Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Lopez LR, Miller CM, Jeyachandran JN, Li C, Simpson KW, Arthur JC. Heterogeneity among clinical intestinal escherichia coli isolates upon acquired streptomycin resistance. Microbiol Spectr. 2023 Jun 15;11(3):e035022. doi: 10.1128/spectrum.03500-22

Ranzani O, Alari A, Olmos S, Mila C, Rico A, Ballester J, Basagana X, Chaccour C, Dadvand P, Duarte-Salles T, Foraster M, Nieuwenhuijsen M, Sunyer J, Valentin A, Kogevinas M, Lazcano U, Avellaneda-Gomez C, Vivanco R, Tonne C. Long-term exposure to air pollution and severe COVID-19 in Catalonia: a population-based cohort study. Nat Commun. 2023 May 24;14(1):2916. doi: 10.1038/s41467-023-38469-7

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22

Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, Garcia-Foncillas J, Candrilli S, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl). 2020 Mar;29(2):e13213. doi: 10.1111/ecc.13213

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862

Turner EE, Jenks M, McCool C, Marshall C, Millar L, Wood H, Peel A, Craig J, Sims AJ. The Memokath-051 stent for the treatment of ureteric obstruction: a NICE medical technology guidance. Appl Health Econ Health Policy. 2018 Aug;16(4):445-64. doi: 10.1007/s40258-018-0389-3

Evans JM, Cleves A, Morgan H, Millar L, Carolan-Rees G. ENDURALIFE-powered cardiac resynchronisation therapy defibrillator devices for treating heart failure: a NICE Medical Technology Guidance. Appl Health Econ Health Policy. 2018 Apr;16(2):177-86. doi: 10.1007/s40258-017-0354-6.

Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpher M, Adams R, Ahmed H, Coles C, Guerrero-Urbano T, Nutting C, Powell M. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy. 2014 Oct;12(5):497-510. doi: 10.1007/s40258-014-0115-8

Karve S, Markowitz M, Fu DJ, Lindenmayer JP, Wang CC, Candrilli SD, Alphs L. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy. 2014 Jun;12(3):335-46.

Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013 May 16;11(3):275-86. doi: 10.1007/s40258-013-0032-2

Karve S, Misurski D, Herrera-Taracena G, Davis KL. Annual all-cause healthcare costs among influenza patients with and without influenza-related complications: analysis of a United States managed care database. Appl Health Econ Health Policy. 2013 Apr 1;11(2):119-28.

Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15.

Davis KL, Bell TJ, Miller JM, Misurski DA, Bapat B. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. Appl Health Econ Health Policy. 2011 May 1;9(3):197-207.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high risk and metastatic melanoma: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009;7(1):31-41.

Anderson H, Espinosa E, Lofts F, Meehan M, Hutchinson G, Price N, Heyes AE. Evaluation of the Chemotherapy Patient Monitor: an interactive tool for facilitating communication between patients and oncologists during the cancer consultation. Eur J Cancer Care (Engl). 2001 Jun;10(2):115-23.